UBS analyst Kevin Caliendo raised the firm’s price target on Cardinal Health (CAH) to $170 from $160 and keeps a Buy rating on the shares. The firm is incrementally positive on the consolidated entity, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- Cardinal Health price target raised to $170 from $156 at Baird
- Cardinal Health Reports Strong Q3 Earnings and Raises Outlook
- Cardinal Health’s Strong Growth Prospects: Emphasizing Pharma and Other Segments Amid Tariff Concerns
- Cardinal Health’s Earnings Call Highlights Growth and Challenges
- Cardinal Health price target raised to $157 from $140 at Citi